MRSA治療薬市場:パイプライン分析・治験・特許・指定・協力・動向

◆英語タイトル:Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
◆商品コード:PSM804039
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2018年2月
◆ページ数:132
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD3,250 ⇒換算¥357,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,750 ⇒換算¥852,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はP&S Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

MRSA infection caused by specific “staph” bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different stages of development.
Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of MRSA are being developed to be administered by the intravenous route which offers good bioavailability and is considered to be more effective at the target site.

Pipeline Supported by Research Funding from Various Agencies

The players in the MRSA therapeutics pipeline have been receiving increasing support from various organizations in the form of research funding. For instance, Microbiotix Inc received Phase l grants from SBIR for “Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus” for a term of two years in February 2012.

MRSA pipeline characterized by Drug candidates with Novel Mechanism of Action

It has been observed that most of the companies are developing drug candidates with novel mechanism of action. Also, the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, GlaxoSmithKline plc is developing a Phase II drug candidate, GSK 2140944 or Gepotidacin. It is an intravenous, synthetic, Type II topoisomerase inhibitor. If GSK2140944 hits the market, it would be the first topoisomerase inhibitor for gram-negative infections. Savara Pharma’s AeroVanc is the first inhaled antibiotic being developed and is in the Phase III stage of clinical trial and has received $5 million fund from Nonprofit Cystic Fibrosis Foundation. If the drug receives the approval, it would be the first inhaled antibiotic to be developed for the treatment of MRSA.

Some of the key players involved in the development of MRSA therapeutics include GlaxoSmithKline plc, Crystal Genomics Inc., and Innovation Pharmaceuticals Inc.

【レポートの目次】

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.2 Causes

4.3 Symptoms

4.3.1 Complications

4.4 Diagnosis

4.5 Treatment

4.6 Prevention of MRSA infection

4.7 Epidemiology

4.8 Key Drivers

4.8.1 Research Funding from Various Agencies

4.8.2 Increasing number of Immune Compromised Population

4.9 Key Barriers

4.9.1 Growing Bacterial Resistance towards Various Antibiotics

4.10 MRSA Therapeutics Pipeline Analysis

4.10.1 Pipeline Analysis by Phase

4.10.2 Pipeline Analysis by Molecule Type

4.10.3 Pipeline Analysis by Route of Administration

4.10.4 Pipeline Analysis by Company

Chapter 5. MRSA Infections Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase III

5.1.1 AeroVanc

5.1.2 XXX

5.1.3 XXX

5.1.4 XXX

5.2 Phase II

5.2.1 CG400549

5.2.2 XXX

5.2.3 XXX

5.2.4 XXX

5.2.4.1 Clinical trials

5.2.4.2 Clinical results

5.2.5 XXX

5.2.6 XXX

5.2.7 XXX

5.2.8 XXX

5.2.9 XXX

5.2.10 XXX

5.2.11 XXX

5.2.12 XXX

5.2.13 XXX

5.2.14 XXX

5.2.15 XXX

5.3 Phase I

5.3.1 AB-SA01

5.3.1.1 Clinical trials

5.3.1.2 Strategic Development

5.3.1.3 Patent

5.3.2 XXX

5.3.2.1 Strategic Development

5.3.2.2 Technology

5.3.3 XXX

5.3.3.1 Strategic Development

5.3.3.2 Technology

5.3.4 XXX

5.3.5 XXX

5.3.5.1 Strategic Development

5.4 Pre-Clinical

5.4.1 Vaccines for MRSA

5.4.1.1 Strategic development

5.4.2 XXX

5.4.2.1 Patent

5.4.3 XXX

5.4.3.1 Strategic development

5.4.4 XXX

5.4.4.1 Strategic developments

5.4.5 XXX

5.4.5.1 Strategic developments

5.4.6 XXX

5.4.6.1 Strategic developments

5.4.7 XXX

5.4.7.1 Strategic developments

5.4.8 XXX

5.4.9 XXX

5.4.9.1 Strategic Development

5.4.10 XXX

5.4.10.1 Strategic developments

5.4.11 XXX

5.4.12 XXX

5.4.13 XXX

5.4.13.1 Pre-Clinical study

5.4.14 XXX

5.4.14.1 Patents

5.4.15 XXX

5.4.15.1 Patent

5.4.16 XXX

5.5 Discovery

5.5.1 AP 138

5.5.2 XXX

5.5.3 XXX

5.5.3.1 Patents

5.5.4 XXX

5.5.4.1 Patents

5.5.5 XXX

5.5.5.1 Patents

5.5.6 XXX

5.5.7 XXX

5.5.8 XXX

5.5.8.1 Strategic developments

5.5.9 XXX

5.6 Unknown

5.6.1 MP106

5.6.2 XXX

5.6.2.1 Strategic Development

5.6.3 XXX

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking

7.2 SWOT Analysis

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 GlaxoSmithKline PLC

8.1.1 Business Overview

8.1.2 Product & Service Offerings

8.2 XXX

8.2.1 Business Overview

8.2.2 Product & Service Offerings

8.3 XXX

8.3.1 Business Overview

8.3.2 Product & Service Offerings

8.4 XXX

8.4.1 Business Overview

8.4.2 Product & Service Offerings

8.5 XXX

8.5.1 Business Overview

8.5.2 Product & Service Offerings

8.6 XXX

8.6.1 Business Overview

8.6.2 Product & Service Offerings

8.7 XXX

8.7.1 Business Overview

8.7.2 Product & Service Offerings

8.8 XXX

8.8.1 Business Overview

8.8.2 Product & Service Offerings

8.9 XXX

8.9.1 Business Overview

8.9.2 Product & Service Offerings

8.10 XXX

8.10.1 Business Overview

8.10.2 Product & Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS OF MRSA INFECTIONS THERAPEUTICS, BY COMPANY (2018)

TABLE 2 DESCRIPTION OF AEROVANC

TABLE 3 DESCRIPTION OF XXX

TABLE 4 DESCRIPTION OF XXX

TABLE 5 DESCRIPTION OF XXX

TABLE 6 DESCRIPTION OF CG400549

TABLE 7 DESCRIPTION OF XXX

TABLE 8 CLINICAL TRIALS OF XXX

TABLE 9 DESCRIPTION OF XXX

TABLE 10 CLINICAL TRIALS OF XXX

TABLE 11 DESCRIPTION OF XXX

TABLE 12 CLINICAL TRIALS OF XXX

TABLE 13 DESCRIPTION OF XXX

TABLE 14 DESCRIPTION OF XXX

TABLE 15 DESCRIPTION OF XXX

TABLE 16 DESCRIPTION OF XXX

TABLE 17 DESCRIPTION OF XXX

TABLE 18 DESCRIPTION OF XXX

TABLE 19 DESCRIPTION OF XXX

TABLE 20 DESCRIPTION OF XXX

TABLE 21 DESCRIPTION OF XXX

TABLE 22 DESCRIPTION OF XXX

TABLE 23 DESCRIPTION OF XXX

TABLE 24 DESCRIPTION OF AB-SA01

TABLE 25 CLINICAL TRIALS OF AB-SA01

TABLE 26 DESCRIPTION OF XXX

TABLE 27 DESCRIPTION OF XXX

TABLE 28 DESCRIPTION OF XXX

TABLE 29 DESCRIPTION OF XXX

TABLE 30 DESCRIPTION OF VACCINE FOR MRSA

TABLE 31 DESCRIPTION OF XXX

TABLE 32 DESCRIPTION OF XXX

TABLE 33 DESCRIPTION OF XXX

TABLE 34 DESCRIPTION OF XXX

TABLE 35 DESCRIPTION OF XXX

TABLE 36 DESCRIPTION OF XXX

TABLE 37 DESCRIPTION OF XXX

TABLE 38 DESCRIPTION OF XXX

TABLE 39 DESCRIPTION OF XXX

TABLE 40 DESCRIPTION OF XXX

TABLE 41 DESCRIPTION OF XXX

TABLE 42 DESCRIPTION OF XXX

TABLE 43 DESCRIPTION OF XXX

TABLE 44 DESCRIPTION OF XXX

TABLE 45 DESCRIPTION OF XXX

TABLE 46 DESCRIPTION OF AP 138

TABLE 47 DESCRIPTION OF XXX

TABLE 48 DESCRIPTION OF XXX

TABLE 49 DESCRIPTION OF XXX

TABLE 50 DESCRIPTION OF XXX

TABLE 51 DESCRIPTION OF XXX

TABLE 52 DESCRIPTION OF XXX

TABLE 53 DESCRIPTION OF XXX

TABLE 54 DESCRIPTION OF XXX

TABLE 55 DESCRIPTION OF XXX

TABLE 56 DESCRIPTION OF XXX

TABLE 57 DESCRIPTION OF XXX

TABLE 58 GLAXOSMITHKLINE PLC – AT A GLANCE

TABLE 59 XXX – AT A GLANCE

TABLE 60 XXX – AT A GLANCE

TABLE 61 XXX – AT A GLANCE

TABLE 62 XXX – AT A GLANCE

TABLE 63 XXX – AT A GLANCE

TABLE 64 XXX – AT A GLANCE

TABLE 65 XXX – AT A GLANCE

TABLE 66 XXX – AT A GLANCE

TABLE 67 XXX – AT A GLANCE

LIST OF FIGURES

FIG 1 RESEARCH METHODOLOGY

FIG 2 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4 MRSA DRUG CANDIDATES IN DEVELOPMENT (2018)

FIG 5 MRSA INFECTIONS PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6 MRSA INFECTIONS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7 BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 8 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 9 KEY PLAYERS BENCHMARKING

FIG 10 SWOT ANALYSIS



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ MRSA治療薬市場:パイプライン分析・治験・特許・指定・協力・動向(Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆